SGLT2-is also appear to act on pancreatic α-cells, leading to an increase in glucagon secretion [36], which promotes β-oxidation of fatty acids, and consequently, reduces liver triglycerides and improves liver steatosis [36,37]. Here, SLC5A2 is linked to fatty liver disease.